Difference between revisions of "Sargramostim (Leukine)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
 
(6 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF), hematopoietic growth factor.  Sargramostim binds to cell surface receptors and stimulates survival, proliferation, and differentiation of hematopoietic progenitor cells. In addition to triggering the proliferation of neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells, GM-CSF has also been observed to activate mature granulocytes and macrophages.<ref name="insert">[http://products.sanofi.us/Leukine/Leukine.pdf Sargramostim (Leukine/GM-CSF) package insert]</ref><ref>[[Media:Sargramostim.pdf|Sargramostim (Leukine/GM-CSF) package insert (locally hosted backup)]]</ref><ref>[http://www.leukine.com Leukine manufacturer's website]</ref>
+
Class/mechanism: Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF), hematopoietic growth factor.  Sargramostim binds to cell surface receptors and stimulates survival, proliferation, and differentiation of hematopoietic progenitor cells. In addition to triggering the proliferation of neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells, GM-CSF has also been observed to activate mature granulocytes and macrophages.<ref name="insert">[http://products.sanofi.us/Leukine/Leukine.pdf Sargramostim (Leukine/GM-CSF) package insert]</ref><ref>[[:File:Sargramostim.pdf|Sargramostim (Leukine/GM-CSF) package insert (locally hosted backup)]]</ref><ref>[http://www.leukine.com Leukine manufacturer's website]</ref>
 
<br>Route: SC, IV
 
<br>Route: SC, IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is used==
 +
''Note: sargramostim does not have a known direct antineoplastic effect. However, it has been used as an adjunct for immunotherapy trials.''
 +
*[[Melanoma]]
 +
*[[Neuroblastoma]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 18: Line 23:
 
<references/>
 
<references/>
  
[[Category:Drug index]]
+
[[Category:Drugs]]
 
[[Category:Subcutaneous medications]]
 
[[Category:Subcutaneous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Granulocyte macrophage colony-stimulating factors]]
 
[[Category:Granulocyte macrophage colony-stimulating factors]]
  
[[Category:Drugs FDA approved in 1991]]
+
[[Category:Melanoma medications]]
 +
[[Category:Neuroblastoma medications]]
 +
 
 +
[[Category:FDA approved in 1991]]

Latest revision as of 00:53, 7 November 2023

General information

Class/mechanism: Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF), hematopoietic growth factor. Sargramostim binds to cell surface receptors and stimulates survival, proliferation, and differentiation of hematopoietic progenitor cells. In addition to triggering the proliferation of neutrophils, monocytes/macrophages, and myeloid-derived dendritic cells, GM-CSF has also been observed to activate mature granulocytes and macrophages.[1][2][3]
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Note: sargramostim does not have a known direct antineoplastic effect. However, it has been used as an adjunct for immunotherapy trials.

Patient drug information

Also known as

  • Generic names: GMCSF, GM-CSF, granulocyte macrophage colony stimulating factor
  • Brand name: Leukine

References